WAYSTAR HOLDING CORP

Company Overview

Waystar is a Utah-based Health Information Services company providing SaaS payment and revenue-cycle solutions to healthcare providers, with over 99% of revenue recurring. Recent results show strong subscription and transaction-driven growth (Q2 revenue up 15.4% YoY), improving operating leverage, elevated Net Revenue Retention (114.6%), and expansion in higher-value clients (1,268 clients >$100k ARR). Management is pursuing inorganic growth—most notably the announced Iodine AI/clinical-intelligence acquisition (priced with cash and shares)—while highlighting seasonality tied to patient volumes and the need to manage integration and financing risks.

Executive Compensation Practices

Given Waystar’s SaaS business model and the filing commentary, executive pay is likely weighted toward equity and performance-based long‑term incentives (RSUs/PSUs) tied to ARR/NRR, subscription expansion, and client growth metrics (e.g., number of >$100k clients). The 10-Q notes a large, nonrecurring IPO-related stock‑based compensation charge in the prior year, so year-over-year compensation expenses can swing materially; future awards may be calibrated to sustain retention post-IPO and to align pay with adjusted EBITDA margin and cash generation. Short‑term incentives are likely tied to revenue/transaction-volume targets and margin/EBITDA improvements, while acquisition execution and integration milestones (e.g., Iodine) may trigger deal-related retention or transaction consideration in equity form.

Insider Trading Considerations

Insiders will be subject to Section 16 reporting (Form 4) and common blackout periods around quarterly earnings, and you should watch for 10b5‑1 trading plans—especially given the volatility introduced by an IPO year and a material M&A deal that uses shares as consideration. Because a meaningful portion of compensation has been and will likely remain equity-based, insiders may time sales after earnings or liquidity events (post‑IPO award vesting, post‑deal announcements), so clusters of insider sales around those events are common. Regulatory and healthcare disclosure sensitivity (privacy, payer disputes, integration risks, financing needs) increases the chance that material nonpublic information will affect trading windows; also monitor dilution and changes in insider ownership when acquisitions are funded with stock, as those transactions often correlate with insider filings and temporary trading restrictions.